论文部分内容阅读
目的探讨心肌梗死不同发病期患者服用血脂康胶囊的冠心病二级预防结果。方法对2135例心肌梗死发病期在28 D至3个月和2735例发病期在3~60个月服用血脂康胶囊治疗的冠心病患者二级预防结果进行分析。结果血脂康治疗组与对照组比较,发病期在28 D至3个月的患者中,冠心病事件减少56.7%(P<0.000 1);总死亡事件减少48.6%(P=0.000 2);发病期在3~60个月之间的患者中,冠心病事件减少35.3%(P=0.000 8),总死亡事件减少20.0%(P=0.118 1)。结论血脂康在发病期28 D至3个月的患者中的疗效好于在发病期3~60个月之间的患者。心肌梗死后患者尽早服用血脂康胶囊可获得更大的预防效果。
Objective To investigate the secondary prevention of coronary heart disease with Xuezhikang capsule in patients with different stages of myocardial infarction. Methods The secondary prevention results of coronary heart disease patients treated with Xuezhikang in 2135 cases of myocardial infarction at 28 D to 3 months and 2735 cases of onset at 3 to 60 months were analyzed. Results Compared with the control group, the incidence of coronary heart disease was decreased by 56.7% (P <0.0001) and the total death was reduced by 48.6% (P = 0.000 2) in the patients with Xuezhikang treatment between 28 and 3 months. Among patients between 3 and 60 months, the incidence of coronary heart disease was reduced by 35.3% (P = 0.0008) and the total deaths were reduced by 20.0% (P = 0.118 1). Conclusion Xuezhikang has a better curative effect in patients with 28D to 3 months of onset than those in the period of 3 to 60 months. As soon as possible after myocardial infarction patients taking Xuezhikang capsule can get greater prevention.